Source: Virtual Congress 2021 – Therapy of lung cancer



Rating:

Share or cite this content

Citations should be made in the following way:
K. Brat (Brno, Czech Republic), J. Skrickova (Brno, Czech Republic), M. Bratova (Brno, Czech Republic), M. Barinova (Brno, Czech Republic), K. Hurdalkova (Brno, Czech Republic), M. Pesek (Pilsen, Czech Republic), M. Svaton (Pilsen, Czech Republic), L. Havel (Prague, Czech Republic), L. Koubkova (Prague, Czech Republic), M. Hrnciarik (Hradec Kralove, Czech Republic), J. Krejci (Prague, Czech Republic), J. Kultan (Olomouc, Czech Republic), O. Fischer (Olomouc, Czech Republic), M. Zemanova (Prague, Czech Republic), M. Cernovska (Prague, Czech Republic), M. Safanda (Prague, Czech Republic), H. Coupkova (Brno, Czech Republic), T. Tuzova (Jihlava, Czech Republic), D. Dolezal (Usti nad Labem, Czech Republic). Progression-free survival with first line treatment as prognostic factor of treatment success in subsequent lines in lung adenocarcinoma patients – who´s the „good responder“?. 2306

Member's Comments

No comment yet.

Related content which might interest you: The importance of the disease-free survival (DFS) endpoint to survivors of lung cancer Source: Virtual Congress 2021 – Screening, diagnosis, management and prognosis of lung cancer Year: 2021 Long-term survival in lung cancer after surgery: is gender a prognostic factor? Source: Eur Respir J 2001; 18: Suppl. 33, 229s Year: 2001 Survival prognosis and target therapy best response in adenocarcinoma lung cancer pts with mutation EGFR gene Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009 Is gender a prognostic factor in long term survival non-small cell lung cancer? Source: Eur Respir J 2002; 20: Suppl. 38, 185s Year: 2002 Rates of treatment response and median survival in advanced non small cell lung cancer patients Source: Eur Respir J 2004; 24: Suppl. 48, 302s Year: 2004 Clinical and biological predictors of progression-free survival (PFS) and overall survival (OS) in patients (pts) with advanced non-small-cell lung cancer (NSCLC) treated by erlotinib in the ERMETIC cohort Source: Annual Congress 2010 - The role of biomarkers in lung cancer Year: 2010 Improved overall survival after early recurrence of lung cancer following the introduction of CT-based follow-up for patients initially treated with curative intent by (chemo)radiotherapy (CRT). Source: International Congress 2017 – Lung cancer: clinically relevant aspects of epidemiology, co-morbidities, metastasised disease and follow-up Year: 2017 The predictive value of neuroendocrine markers for response to chemotherapy and survival in patients with non-small cell lung Source: Eur Respir J 2006; 28: Suppl. 50, 386s Year: 2006 Epidemiological and clinical predictors of survival during the first year of the treatment in non-small cell lung cancer patients Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009 Survival outcomes of non small cell lung cancer (NSCLC) patients who are suitable for radical treatment at initial presentation Source: Annual Congress 2011 - Quality management for lung cancer patients Year: 2011 Limited role of Ki-67 in lung carcinoid tumor patients predicting overall short-term survival,A single institution experience Source: International Congress 2018 – Lung cancer: novel prognostic markers and scores Year: 2018 Long-term survival of the patients with advanced non small cell lung carcinomas after induction chemotherapy Source: Eur Respir J 2005; 26: Suppl. 49, 78s Year: 2005 Improved overall survival after late recurrence of lung cancer following the introduction of CT-based follow-up for patients treated with curative intent Source: International Congress 2018 – Lung cancer: from early diagnosis to modern monitoring strategies Year: 2018 Identification of p-stage I NSCLC patients with high risk of recurrence and poor prognosis by tumor marker index (TMI) Source: Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics Year: 2011 Determining values of prognostic factors with patients with NSCLC based on two years survival Source: Annual Congress 2007 - Lung neoplasms Year: 2007 Clinical factors of long-term survival in patients with advanced lung cancer Source: International Congress 2017 – Lung cancer: clinically relevant aspects of epidemiology, co-morbidities, metastasised disease and follow-up Year: 2017 Gefitinib in the non small cell lung cancer treatment: contribution to prolongation and quality of survival Source: Eur Respir J 2004; 24: Suppl. 48, 303s Year: 2004 Impact of radiotherapy on survival rates in chemotherapy treated non small cell lung cancer patients Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009 Importance of CYFRA-21 in estimation of survival of patients with NSCLC Source: Eur Respir J 2006; 28: Suppl. 50, 85s Year: 2006 Survival of patients with relapsing small cell lung cancer (SCLC) after new line chemotherapy administration Source: Eur Respir J 2005; 26: Suppl. 49, 78s Year: 2005